In Vitro Dissolution and in Silico Modeling Shortcuts in Bioequivalence Testing.

Clicks: 355
ID: 82250
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #17 of 55 articles by views in Pharmaceutics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
To review in vitro testing and simulation platforms that are in current use to predict in vivo performances of generic products as well as other situations to provide evidence for biowaiver and support drug formulations development.Pubmed and Google Scholar databases were used to review published literature over the past 10 years. The terms used were "simulation AND bioequivalence" and "modeling AND bioequivalence" in the title field of databases, followed by screening, and then reviewing.A total of 22 research papers were reviewed. Computer simulation using software such as GastroPlus™, PK-Sim and SimCyp find applications in drug modeling. Considering the wide use of optimization for in silico predictions to fit observed data, a careful review of publications is required to validate the reliability of these platforms. For immediate release (IR) drug products belonging to the Biopharmaceutics Classification System (BCS) classes I and III, difference factor () and similarity factor () are calculated from the in vitro dissolution data of drug formulations to support biowaiver; however, this method can be more discriminatory and may not be useful for all dissolution profiles.Computer simulation platforms need to improve their mechanistic physiologically based pharmacokinetic (PBPK) modeling, and if prospectively validated within a small percentage of error from the observed clinical data, they can be valuable tools in bioequivalence (BE) testing and formulation development.
Reference Key
altabakha2020inpharmaceutics Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Al-Tabakha, Moawia M;Alomar, Muaed J;
Journal Pharmaceutics
Year 2020
DOI
E45
URL
Keywords
dissolution bioequivalence publication bias biowaiver biopharmaceutics classification system in silico pharmacokinetic simulations similarity factor

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.